BH.IMMUN&BIO | ZOTA HEALTH CARE | BH.IMMUN&BIO/ ZOTA HEALTH CARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -5.9 | -44.5 | - | View Chart |
P/BV | x | 1.2 | 17.2 | 6.7% | View Chart |
Dividend Yield | % | 0.0 | 0.2 | - |
BH.IMMUN&BIO ZOTA HEALTH CARE |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
ZOTA HEALTH CARE Mar-24 |
BH.IMMUN&BIO/ ZOTA HEALTH CARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 555 | 9.3% | |
Low | Rs | 21 | 270 | 7.6% | |
Sales per share (Unadj.) | Rs | 10.3 | 69.8 | 14.8% | |
Earnings per share (Unadj.) | Rs | -3.9 | -5.6 | 69.4% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 2.2 | -171.5% | |
Dividends per share (Unadj.) | Rs | 0 | 1.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.2 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 34.8 | 58.7% | |
Shares outstanding (eoy) | m | 43.18 | 25.85 | 167.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 5.9 | 59.2% | |
Avg P/E ratio | x | -9.4 | -74.3 | 12.6% | |
P/CF ratio (eoy) | x | -9.5 | 185.8 | -5.1% | |
Price / Book Value ratio | x | 1.8 | 11.8 | 14.9% | |
Dividend payout | % | 0 | -18.0 | 0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 10,662 | 14.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 292 | 51.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 1,804 | 24.7% | |
Other income | Rs m | 11 | 12 | 91.7% | |
Total revenues | Rs m | 457 | 1,815 | 25.2% | |
Gross profit | Rs m | -161 | 76 | -212.7% | |
Depreciation | Rs m | 2 | 201 | 1.0% | |
Interest | Rs m | 71 | 48 | 147.5% | |
Profit before tax | Rs m | -223 | -162 | 137.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | -18 | 310.1% | |
Profit after tax | Rs m | -166 | -143 | 116.0% | |
Gross profit margin | % | -36.0 | 4.2 | -860.0% | |
Effective tax rate | % | 25.3 | 11.2 | 225.1% | |
Net profit margin | % | -37.3 | -8.0 | 468.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 1,116 | 32.1% | |
Current liabilities | Rs m | 940 | 737 | 127.6% | |
Net working cap to sales | % | -130.6 | 21.0 | -620.8% | |
Current ratio | x | 0.4 | 1.5 | 25.1% | |
Inventory Days | Days | 85 | 10 | 877.8% | |
Debtors Days | Days | 1,135 | 551 | 205.9% | |
Net fixed assets | Rs m | 1,262 | 1,123 | 112.4% | |
Share capital | Rs m | 432 | 258 | 167.1% | |
"Free" reserves | Rs m | 450 | 641 | 70.2% | |
Net worth | Rs m | 882 | 900 | 98.0% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 2,239 | 72.3% | |
Interest coverage | x | -2.2 | -2.4 | 90.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.8 | 34.2% | |
Return on assets | % | -5.9 | -4.3 | 138.5% | |
Return on equity | % | -18.9 | -15.9 | 118.3% | |
Return on capital | % | -17.2 | -12.6 | 136.4% | |
Exports to sales | % | 0 | 8.8 | 0.0% | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | 160 | 0.0% | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 160 | 0.0% | |
Fx outflow | Rs m | 65 | 10 | 642.6% | |
Net fx | Rs m | -65 | 150 | -43.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | -60 | -182.0% | |
From Investments | Rs m | 5 | -129 | -3.6% | |
From Financial Activity | Rs m | -147 | 188 | -78.4% | |
Net Cashflow | Rs m | -34 | -1 | 3,051.8% |
Indian Promoters | % | 59.3 | 62.4 | 95.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 1.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 37.6 | 108.4% | |
Shareholders | 35,313 | 8,937 | 395.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.3 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | ZOTA HEALTH CARE | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 2.43% | 3.04% | 1.23% |
1-Month | -8.41% | -4.87% | -0.24% |
1-Year | -5.63% | 38.19% | 43.62% |
3-Year CAGR | -21.40% | 16.15% | 20.35% |
5-Year CAGR | 24.39% | 24.99% | 26.24% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the ZOTA HEALTH CARE share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of ZOTA HEALTH CARE the stake stands at 62.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of ZOTA HEALTH CARE.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
ZOTA HEALTH CARE paid Rs 1.0, and its dividend payout ratio stood at -18.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of ZOTA HEALTH CARE.
For a sector overview, read our pharmaceuticals sector report.
After opening the day higher, Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.